Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2005;46:1186-1193
Published online before print October 3, 2005, doi: 10.1161/01.HYP.0000185688.81320.4d
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/5/1186    most recent
01.HYP.0000185688.81320.4dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stranges, S.
Right arrow Articles by Donahue, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stranges, S.
Right arrow Articles by Donahue, R. P.
Related Collections
Right arrow Epidemiology
Right arrow Obesity
Right arrow Type 2 diabetes
Right arrow Risk Factors

(Hypertension. 2005;46:1186.)
© 2005 American Heart Association, Inc.


Original Articles

Body Fat Distribution, Liver Enzymes, and Risk of Hypertension

Evidence From the Western New York Study

Saverio Stranges; Maurizio Trevisan; Joan M. Dorn; Jacek Dmochowski; Richard P. Donahue

From the Department of Social and Preventive Medicine (S.S., M.T., J.M.D., J.D., R.P.D.), State University of New York at Buffalo; and the Department of Mathematics and Statistics (J.D.), University of North Carolina–Charlotte.

Correspondence to Saverio Stranges, MD, PhD, Department of Social & Preventive Medicine, School of Public Health and Health Professions, State University of New York at Buffalo, 3435 Main St, Farber Hall, Rm 272, Buffalo, NY 14214. E-mail stranges{at}buffalo.edu

{gamma}-Glutamyltransferase (GGT) has been associated with hypertension (HTN); however, the nature of this association remains unclear. GGT is a marker of alcohol consumption, but it is also related to the infiltration of fat in the liver (fatty liver). The association between GGT and HTN was examined in a 6-year longitudinal investigation among 1455 men and women who returned for the follow-up visit. Baseline variables included serum GGT, blood pressure, and anthropometric measures. Incident HTN was defined as blood pressure ≥140/90 or on antihypertensive medication at the follow-up visit. To eliminate individuals with potential liver pathology, analyses focused only on individuals with GGT within its normal range (n=897). Participants were divided in quintiles (Q) based on their baseline GGT levels. Multiple logistic regression analyses [odds ratio (95% confidence intervals)] revealed a significant association of GGT with incident hypertension [2.1 (1.1 to 4.0) Q5 versus Q1]. In subgroup analyses, GGT and HTN were significantly associated among both noncurrent and current drinkers, but only for participants above the median of anthropometric measures [eg, body mass index >26.4, 2.3 (0.9 to 5.7), waist circumference >86.1 cm, 3.7 (1.4 to 9.9), and abdominal height >19.8 cm, 3.1 (1.2 to 8.5), for Q5 versus Q1, in fully adjusted models]. These findings suggest that the association between GGT and hypertension is not caused solely by alcohol consumption and indicate that serum GGT, within its normal range, may predict hypertension among individuals with increased central fat distribution, suggesting that fatty liver may represent an important underlying mechanism for this association.


Key Words: adipose tissue • blood pressure • epidemiology • hypertension • liver




This article has been cited by other articles:


Home page
Alcohol AlcoholHome page
A. M. Baros, T. M. Wright, P. K. Latham, P. M. Miller, and R. F. Anton
Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment
Alcohol Alcohol., March 1, 2008; 43(2): 192 - 197.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. P. Donahue, S. Stranges, K. Rejman, L. B. Rafalson, J. Dmochowski, and M. Trevisan
Elevated Cystatin C Concentration and Progression to Pre-Diabetes: The Western New York Study
Diabetes Care, July 1, 2007; 30(7): 1724 - 1729.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Grundy
Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 4 - 7.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. S. Lee, J. C. Evans, S. J. Robins, P. W. Wilson, I. Albano, C. S. Fox, T. J. Wang, E. J. Benjamin, R. B. D'Agostino, and R. S. Vasan
Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. J. Beilin and I. B. Puddey
Alcohol and Hypertension: An Update
Hypertension, June 1, 2006; 47(6): 1035 - 1038.
[Full Text] [PDF]


Home page
CirculationHome page
P. Giral, V. Ratziu, J. C. Chapman, E. Ruttmann, H. Ulmer, L. J. Brant, H. Concin, G. Diem, and K. Rapp
Letter Regarding Article by Ruttmann et al, "{gamma}-Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality: An Epidemiological Investigation in a Cohort of 163 944 Austrian Adults"
Circulation, February 28, 2006; 113(8): e299 - e300.
[Full Text] [PDF]